"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Epidemiology of coagulation factor deficiency & hemophilia
4.2 Recent industry developments such as mergers & acquisitions
4.3 Regulatory scenario in key countries
4.4 New products launch
4.5 Pipeline analysis
4.6 Reimbursement scenario
4.7 Key industry trends
5. Global Hemophilia Drugs Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings/ Summary
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1 Hemophilia A
5.2.2 Hemophilia B
5.2.3 Hemophilia C
5.3 Market Analysis, Insights and Forecast – By Type
5.3.1 Recombinant Therapy
5.3.2 Plasma-derived
5.3.3 Others
5.4. Market Analysis, Insights and Forecast – By End User
5.4.1 Hospital Pharmacy
5.4.2 Retail Pharmacy
5.4.3 Online Pharmacy
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1 North America
5.5.2 Europe
5.5.3 Asia Pacific
5.5.4 Latin America
5.5.5 Middle East & Africa
6. North America Hemophilia Drugs Market Analysis, Insights and Forecast,2015-2026
6.1. Key Findings/ Summary
6.2. Market Analysis – By Application
6.2.1 Hemophilia A
6.2.2 Hemophilia B
6.2.3 Hemophilia C
6.3. Market Analysis – By Type
6.3.1 Recombinant Therapy
6.3.2 Plasma-derived
6.3.3 Others
6.4. Market Analysis – By End User
6.4.1 Hospital Pharmacy
6.4.2 Retail Pharmacy
6.4.3 Online Pharmacy
6.5. Market Analysis – By Country
6.5.1 U.S.6.5.2 Canada
7. Europe Hemophilia Drugs Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings/Summary
7.2. Market Analysis – By Application
7.2.1 Hemophilia A
7.2.2 Hemophilia B
7.2.3 Hemophilia C
7.3. Market Analysis – By Type
7.3.1 Recombinant Therapy
7.3.2 Plasma-derived
7.3.3 Others
7.4. Market Analysis – By End User
7.4.1 Hospital Pharmacy
7.4.2 Retail Pharmacy
7.4.3 Online Pharmacy
7.5. Market Analysis – By Country
7.5.1 Germany
7.5.2 U.K
7.5.3 France
7.5.4 Italy
7.5.5 Spain
7.5.6 Scandinavia
7.5.7 Rest of Europe
8. Asia Pacific Hemophilia Drugs Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings/ Summary
8.2. Market Analysis – By Application
8.2.1 Hemophilia A
8.2.2 Hemophilia B
8.2.3 Hemophilia C
8.3. Market Analysis – By Type
8.3.1 Recombinant Therapy
8.3.2 Plasma-derived
8.3.3 Others
8.4. Market Analysis – By End User
8.4.1 Hospital Pharmacy
8.4.2 Retail Pharmacy
8.4.3 Online Pharmacy
8.5. Market Analysis – By Country/Sub-region
8.5.1 India
8.5.2 China
8.5.3 Japan
8.5.4 Australia
8.5.5 Southeast Asia
8.5.6 Rest of Asia Pacific
9. Latin America Hemophilia Drugs Market Analysis, Insights and Forecast,2015-2026
9.1. Key Findings/ Summary
9.2. Market Analysis – By Application
9.2.1 Hemophilia A
9.2.2 Hemophilia B
9.2.3 Hemophilia C
9.3. Market Analysis – By Type
9.3.1 Recombinant Therapy
9.3.2 Plasma-derived
9.3.3 Others
9.4. Market Analysis – By End User
9.4.1 Hospital Pharmacy
9.4.2 Retail Pharmacy
9.4.3 Online Pharmacy
9.5. Market Analysis – By Country/Sub-region
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
10. Middle East & Africa Hemophilia Drugs Market Analysis, Insights andForecast, 2015-2026
10.1. Key Findings/Summary
10.2. Market Analysis – By Application
10.2.1 Hemophilia A
10.2.2 Hemophilia B
10.2.3 Hemophilia C
10.3. Market Analysis – By Type
10.3.1 Recombinant Therapy
10.3.2 Plasma-derived
10.3.3 Others
10.4. Market Analysis – By End User
10.4.1 Hospital Pharmacy
10.4.2 Retail Pharmacy
10.4.3 Online Pharmacy
10.5. Market Analysis – By Country/Sub-region
10.5.1 South Africa
10.5.2 GCC
10.5.3 Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.5.1 Grifols SA
11.5.2 FERRING LÄKEMEDEL AB
11.5.3 Aptevo Therapeutics
11.5.4 F. Hoffmann-La Roche Ltd
11.5.5 Novo Nordisk
11.5.6 Pfizer, Inc.,
11.5.7 CSL Limited
11.5.8 Bioverativ Inc.
11.5.9 Octapharma AG,
12. Strategic Recommendations
Related Reports